Phase I study of UCN-01 and ara-C for patients with refractory or relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

被引：0
|
作者：
Cortes, J
Plunkett, WK
Estey, EH
Keating, MJ
Madden, T
Sampath, D
Faderl, S
Beran, M
Dancey, J
Kantarjian, HM
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] NCI, CTEP, Bethesda, MD 20892 USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4555
引用
收藏
页码：211B / 211B
页数：1
相关论文
共 50 条
  • [21] Clofarabine plus cytarabine (ARA-C) combination is active in newly diagnosed patients (pts) ≥ age 50 with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Faderl, S
    Gandhi, V
    Verstovsek, S
    Cortes, J
    Ravandi-Kashani, F
    Beran, M
    Garcia-Manero, G
    Koller, C
    O'Brien, S
    Ferrajoli, A
    Estrov, Z
    Kwari, M
    Plunkett, W
    Kantarjian, HM
    BLOOD, 2004, 104 (11) : 250A - 250A
  • [22] Phase I evaluation of tipifarnib in combination with low-dose Ara-C (LDAC) in high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Interim results
    Cortes, J. E.
    Feldman, E. J.
    Douer, D.
    Raza, A.
    Fruchtman, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] CLOFARABINE IN COMBINATION WITH CYTARABINE (ARA-C) FOR TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA IN ADULT PATIENTS
    Malato, A.
    Santoro, A.
    Magrin, S.
    Felice, R.
    Turri, D.
    Di Bella, R.
    Salemi, D.
    Acquaviva, F.
    Scime, R.
    Fabbiano, F.
    HAEMATOLOGICA, 2012, 97 : 502 - 503
  • [24] A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Wilhelm, Francois
    Hearn, Katherine
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Azarnia, Nozar
    Silverman, Lewis R.
    BLOOD, 2014, 124 (21)
  • [25] Phase I Study of Bortezomib Combined with Lenalidomide for Relapsed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Following Hematopoietic Cell Transplantation
    Brunner, Andrew M.
    Blonquist, Traci M.
    McMasters, Malgorzata
    Hobbs, Gabriela S.
    McAfee, Steven L.
    Rosenblatt, Jacalyn
    Amrein, Philip C.
    El-Jawahri, Areej
    Connolly, Christine
    Ramos, Aura
    Mikami, Kaleb
    Logan, Emma
    Dey, Bimalangshu R.
    Spitzer, Thomas
    Avigan, David E.
    Fathi, Amir T.
    Chen, Yi-Bin
    Ballen, Karen
    BLOOD, 2017, 130
  • [26] Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant Myelodysplastic Syndrome (MDS)
    Garcia-Manero, Guillermo
    Kurman, Michael R.
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Alvarado, Yesid
    Naqvi, Kiran
    Ravandi, Farhad
    Jabbour, Elias J.
    Delumpa, Ricardo
    Madden, Timothy
    Maier, Gary
    Iwamura, Hiroyuki
    Kantarjian, Hagop M.
    BLOOD, 2018, 132
  • [27] Treatment with high dose Ara-C and Topotecan for relapsed/refractory acute myelogenous leukemia (AML).
    Case, DC
    Ebrahim, KS
    Aronson, FR
    Hedlund, JA
    BLOOD, 2000, 96 (11) : 209B - 209B
  • [28] Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia
    Cortes, J
    Estey, E
    Beran, M
    O'Brien, S
    Giles, F
    Koller, C
    Keating, M
    Kantarjian, H
    LEUKEMIA & LYMPHOMA, 2000, 36 (5-6) : 479 - 484
  • [29] A phase I/II study of topotecan, mitoxantrone and etoposide in relapsed/refractory acute myeloid leukemia (AML), myeloid blast crisis and high risk myelodysplastic syndromes (MDS).
    Nand, S
    Stiff, P
    Beltran, O
    Godwin, J
    BLOOD, 1999, 94 (10) : 234B - 234B
  • [30] Clofarabine is active in combination with cytarabine (ara-C) in adult patients (pts) in first relapsed and primary refractory acute leukemia and high-risk myelodysplastic syndrome (MDS).
    Faderl, S
    Gandhi, V
    Garcia-Manero, G
    Thomas, DA
    Cortes, JE
    O'Brien, S
    Estey, E
    Craig, A
    Weiss, J
    Keating, M
    Verstovsek, S
    Giles, FJ
    Kwari, M
    Plunkett, W
    Kantarjian, HM
    BLOOD, 2003, 102 (11) : 615A - 615A
12345